Skip to main content

AstraZeneca turnaround is 3-4 year journey, says CEO

Turning around drugmaker AstraZeneca will be a long haul, with a strategy of revamping research and boosting acquisitions set to take up to four years to pay off, its chief executive said on Tuesday.

Speaking as the group unveiled the location for a new global headquarters and research center in Cambridge, England, Pascal Soriot said he was not expecting any short-term fixes for the group, which is struggling from falling sales as patents expire.

"You've got to look at this over a horizon of three to four years, it is not a six-month horizon," he said in a telephone interview from Cambridge. "And it is not going to be a smooth journey. We will have ups and downs."

The company's new $500 million site on the southern outskirts of the university town, which will be purpose-built, is only set for completion in 2016.

 

However, AstraZeneca plans to transfer some staff from its existing Alderley Park facility in northwest England before then, possibly as early as the end of 2013, using rented laboratories and offices.

"We will have people based here potentially at the end of the year and we will start benefiting from the location," Soriot said.

Cambridge is a major centre for life science research, which Soriot said could rival San Francisco and Boston, and he hopes to tap into that knowledge base by having his scientists working close to top academics and clinicians.

Targeted acquisitions in three key areas - cardiovascular and metabolic medicine, oncology, and respiratory and inflammatory drugs - are another important plank of Soriot's turnaround plan.

Despite urgings from some analysts, he has eschewed large-scale deals, preferring to focus instead on bolt-on acquisitions, often of private companies, such as last week's purchase of Pearl for up to $1.15 billion.

Britain's second-biggest drugmaker has suffered from a series of failures of experimental medicines that have weakened its pipeline, forcing it to go shopping for promising new drugs invented by smaller biotech companies.

"We will keep looking at potential deals to keep building our pipeline," Soriot said.

"You will see by the end of the year or early next year that our late-stage pipeline will look very different as a result of some of those acquisitions, but also with the acceleration of some of our Phase II projects that are moving into Phase III right now."

Among existing products, investors are focused on prospects for diabetes drug Onglyza, co-owned with Bristol-Myers Squibb, which may show a cardiovascular benefit in a clinical trial - an outcome that would give it a marketing edge.

Soriot said headline results of the so-called SAVOR study were due "in the next few days", but he declined to comment further on the findings.

(Editing by Greg Mahlich)

Popular posts from this blog

Study Abroad USA, College of Charleston, Popular Courses, Alumni

Thinking for Study Abroad USA. School of Charleston, the wonderful grounds is situated in the actual middle of a verifiable city - Charleston. Get snatched up by the wonderful and customary engineering, beautiful pathways, or look at the advanced steel and glass building which houses the School of Business. The grounds additionally gives students simple admittance to a few major tech organizations like Amazon's CreateSpace, Google, TwitPic, and so on. The school offers students nearby as well as off-grounds convenience going from completely outfitted home lobbies to memorable homes. It is prepared to offer different types of assistance and facilities like clubs, associations, sporting exercises, support administrations, etc. To put it plainly, the school grounds is rising with energy and there will never be a dull second for students at the College of Charleston. Concentrate on Abroad USA is improving and remunerating for your future. The energetic grounds likewise houses various

Best MBA Online Colleges in the USA

“Opportunities never open, instead we create them for us”. Beginning with this amazing saying, let’s unbox today’s knowledge. Love Business and marketing? Want to make a high-paid career in business administration? Well, if yes, then mate, we have got you something amazing to do!   We all imagine an effortless future with a cozy house and a laptop. Well, well! You can make this happen. Today, with this guide, we will be exploring some of the top-notch online MBA universities and institutes in the USA. Let’s get started! Why learn Online MBA from the USA? Access to More Options This online era has given a second chance to children who want to reflect on their careers while managing their hectic schedules. In this, the internet has played a very crucial in rejuvenating schools, institutes, and colleges to give the best education to students across the globe. Graduating with Less Debt Regular classes from high reputed institutes often charge heavy tuition fees. However onl

Sickening moment maskless 'Karen' COUGHS in the face of grocery store customer, then claims she doesn't have to wear a mask because she 'isn't sick'

A woman was captured on camera following a customer through a supermarket as she coughs on her after claiming she does not need a mask because she is not sick.  Video of the incident, which has garnered hundreds of thousands of views on Twitter alone, allegedly took place in a Su per Saver in Lincoln, Nebraska according to Twitter user @davenewworld_2. In it, an unidentified woman was captured dramatically coughing as she smiles saying 'Excuse me! I'm coming through' in the direction of the customer recording her. Scroll down for video An unidentified woman was captured dramatically coughing as she smiles saying 'Excuse me! I'm coming through' in the direction of a woman recording her A woman was captured on camera following a customer as she coughs on her in a supermarket without a mask on claiming she does not need one because she is not sick @chaiteabugz #karen #covid #karens #karensgonewild #karensalert #masks we were just wearing a mask at the store. ¿ o